Monte Rosa Therapeutics, Inc. (GLUE)
| Market Cap | 1.53B +280.0% |
| Revenue (ttm) | 42.95M -73.1% |
| Net Income | -130.01M |
| EPS | -1.50 |
| Shares Out | 84.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 926,125 |
| Open | 18.46 |
| Previous Close | 18.68 |
| Day's Range | 17.93 - 18.54 |
| 52-Week Range | 3.51 - 25.77 |
| Beta | 1.62 |
| Analysts | Strong Buy |
| Price Target | 31.75 (+74.93%) |
| Earnings Date | May 7, 2026 |
About GLUE
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1α, IL-1β and IL... [Read more]
Financial Performance
In 2025, Monte Rosa Therapeutics's revenue was $123.67 million, an increase of 63.54% compared to the previous year's $75.62 million. Losses were -$38.63 million, -46.87% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for GLUE stock is "Strong Buy." The 12-month stock price target is $31.75, which is an increase of 74.93% from the latest price.
News
Monte Rosa Therapeutics price target raised to $31 from $30 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $31 from $30 and keeps an Overweight rating on the shares.
Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M
“We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching Phase 2 trial initiations,” said Markus Warmuth, Chief...
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with ele...
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today anno...
Monte Rosa Therapeutics to present preclinical data on MRT-55811
Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data highlighting the potential of its highly selective, first-in-class cyclin E1-directed MGD, MRT-55811, to treat CCNE1-...
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectiv...
Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim
Guggenheim lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $30 from $34 and keeps a Buy rating on the shares. The firm, which is updating its model…
Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M
Collaboration revenue in the same quarter last year was $60.65M. Net loss for the fourth quarter of 2025 was $46.1M, compared to $13.4M for the fourth quarter of 2024. Expects…
Monte Rosa Therapeutics reports Q4 revenue $2.8M, consensus $15.51
Expects its cash and cash equivalents to be sufficient to fund planned operations and capital expenditures into 2029. “Monte Rosa is now on the cusp of Phase 2 trial initiations…
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipat...
Monte Rosa Therapeutics announces clinical supply agreement with Johnson & Johnson
Monte Rosa Therapeutics (GLUE) announced the company has entered into a supply agreement with Johnson & Johnson to evaluate MRT-2359 in combination with ERLEADA for the treatment of patients with…
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment
Monte Rosa Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Molecular glue degraders are advancing clinical programs targeting undruggable proteins, with MRT-8102 showing strong CRP reduction and safety in early studies. Key catalysts include GFORCE-1 data in H2 2024, phase II trials for MRT-6160, and a signal-confirming study for MRT-2359 in AR-mutant prostate cancer.
Monte Rosa Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing a pipeline of molecular glue degraders, with strong clinical data in NEK7 and GSPT1 programs and multiple phase II trials set for 2024. Strategic partnerships and a robust financial position support expansion into new indications and second-generation molecules.
Monte Rosa announces clinical data from Phase 1/2 study of MRT-2359
Monte Rosa Therapeutics (GLUE) announced updated, positive clinical data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients wi...
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, in...
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann...
Monte Rosa Therapeutics files automatic mixed securities shelf
16:37 EST Monte Rosa Therapeutics (GLUE) files automatic mixed securities shelf
Monte Rosa Therapeutics price target raised to $37 from $27.50 at Piper Sandler
Piper Sandler raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $37 from $27.50 and keeps an Overweight rating on the shares. The firm notes Monte Rosa reported…
Monte Rosa Therapeutics 11.125M share Secondary priced at $24.00
The deal size was increased to $300M in common stock and pre-funded warrants from $200M. Jefferies, TD Cowen and Piper Sandler acted as joint book running managers for the offering.
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc . (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medi...
Monte Rosa Therapeutics announces $200M common stock offering
Monte Rosa Therapeutics (GLUE) announced that it has commenced an underwritten public offering of $200M of shares of its common stock and, in lieu of common stock to certain investors,…
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medic...
Monte Rosa Therapeutics price target raised to $31 from $22 at Jefferies
Jefferies raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $31 from $22 and keeps a Buy rating on the shares after MRT-8102 showed deep reduction of inflammatory…
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush
Wedbush raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $37 from $26 and keeps an Outperform rating on the shares after the company announced positive interim data…